Frontiers in Pharmacology

Cost-utility analysis of simultaneous initiation of finerenone and empagliflozin for type 2 diabetes mellitus complicated with chronic kidney disease

By Qiang Liu, Jiangang Lu, Fengning Chuan, Longbing Lai

Computational studyInterventions

The paper

Qiang Liu, Jiangang Lu, Fengning Chuan, Longbing Lai

Shenyang Pharmaceutical University; Chongqing University

Frontiers in Pharmacology, 20 Jul 2026

doi.org/10.3389/fphar.2026.1847907 PubMed 42549165

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes